An analysis of baseline blood samples from 140 melanoma patients treated with anti-CTLA-4 therapy found that only low baseline IL-6 levels (< 2.5 ng/L) and female sex were correlated with an increased risk of Grade ≥ 3 irAEs after adjustment for follow-up time [5]. Here, CTLA4 is linked to melanoma.